We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
biotechnology: Archive
Here's How to Find Cheap Stocks Under $10 to Buy for December
by Benjamin Rains
Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...
MGNXPositive Net Change NINEPositive Net Change
biotechnology oil-energy
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
by Zacks Equity Research
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
BIIBNegative Net Change GILDPositive Net Change SLDBNegative Net Change CINCNegative Net Change
biotechnology pharmaceuticals
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
BIIBNegative Net Change GILDPositive Net Change SLDBNegative Net Change RCUSPositive Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Affiliated Managers Group (AMG)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Caterpillar (CAT) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CATPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Meridian Bank (MRBK)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MRBKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Puma Biotech (PBYI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PBYIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Lattice Semiconductor (LSCC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LSCCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Eagle Alternative (FCRD) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FCRDNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Precision Drilling (PDS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PDSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
JAPAN TOB (JAPAY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
JAPAYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Banco Bilbao (BBVA) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BBVAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Axcelis Technologies (ACLS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ACLSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
NVSNegative Net Change LLYNegative Net Change INCYNegative Net Change SNDXNegative Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Outperforms YTD: What's in Store for 2023?
by Zacks Equity Research
Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.
REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology pharmaceuticals
MidWestOne (MOFG)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
MOFGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Asure Software Inc (ASUR)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ASURPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
by Zacks Equity Research
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
REGNNegative Net Change CTMXNegative Net Change APLSNegative Net Change INMNegative Net Change
biotechnology biotechs pharmaceuticals
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
REGNNegative Net Change SNYPositive Net Change BIIBNegative Net Change SNDXNegative Net Change
biotechnology biotechs
United Rentals (URI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
URINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GLYCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Grand Canyon Education (LOPE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
LOPENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
PDF Solutions (PDFS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PDFSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Univest (UVSP)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
UVSPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Prothena (PRTA) Earns Milestone Payment From Novo Nordisk
by Zacks Equity Research
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs